

Documents

Roney, M.^{a b}, Singh, G.^{c d}, Huq, A.K.M.M.^{b e}, Forid, M.S.^f, Ishak, W.M.B.W.^f, Rullah, K.^g, Aluwi, M.F.F.M.^{a b}, Tajuddin, S.N.^{a b}

Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches

(2023) *Molecular Biotechnology*, .

DOI: 10.1007/s12033-023-00667-5

^a Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Pahang Darul Makmur, Gambang, Kuantan, 26300, Malaysia

^b Bio Aromatic Research Centre, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Pahang Darul Makmur, Gambang, Kuantan, 26300, Malaysia

^c Section of Microbiology, Central Ayurveda Research Institute, Uttar Pradesh, Jhansi, India

^d Kusuma School of Biological Sciences, Indian Institute of Technology, Delhi, India

^e School of Medicine, Department of Pharmacy, University of Asia Pacific, 74/A, Green Road, Dhaka, 1205, Bangladesh

^f Faculty of Chemical and Processing Engineering Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Pahang Darul Makmur, Gambang, Kuantan, 26300, Malaysia

^g Kulliyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, Kuantan, Pahang, 25200, Malaysia

Abstract

The infection produced by the SARS-CoV-2 virus remains a significant health crisis worldwide. The lack of specific medications for COVID-19 necessitates a concerted effort to find the much-desired therapies for this condition. The main protease (Mpro) of SARS-CoV-2 is a promising target, vital for virus replication and transcription. In this study, fifty pyrazole derivatives were tested for their pharmacokinetics and drugability, resulting in eight hit compounds. Subsequent molecular docking simulations on SARS-CoV-2 main protease afforded two lead compounds with strong affinity at the active site. Additionally, the molecular dynamics (MD) simulations of lead compounds (17 and 39), along with binding free energy calculations, were accomplished to validate the stability of the docked complexes and the binding poses achieved in docking experiments. Based on these findings, compound 17 and 39, with their favorable projected pharmacokinetics and pharmacological characteristics, are the proposed potential antiviral candidates which require further investigation to be used as anti-SARS-CoV-2 medication. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Author Keywords

ADMET; Docking; Drug-likeness; Molecular dynamics simulation; Pyrazole derivatives of Usnic acid; SARS-CoV-2

Index Keywords

Binding energy, Diseases, Free energy, Lead compounds, Molecular dynamics, Pharmacokinetics; ADMET, Docking, Drug-likeness, Dynamics simulation, Molecular dynamic simulation, Pyrazole derivative of usnic acid, Pyrazole derivatives, Screening approaches, Usnic acid, Virtual Screening; Coronavirus

References

- Cavasotto, C.N., Di Filippo, J.I.
In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking
(2021) *Molecular Informatics*, 40 (1), p. 2000115.
COI: 1:CAS:528:DC%2BB3cXhs1WitrnM
- Hui, D.S., Azhar, E.I., Madani, T.A., Ntoumi, F., Kock, R., Dar, O., Petersen, E.
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health —The latest 2019 novel coronavirus outbreak in Wuhan, China
(2020) *International Journal of Infectious Diseases*, 91, pp. 264-266.
COI: 1:CAS:528:DC%2BB3cXnsVaisbg%3D
- Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Hilgenfeld, R.
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors

- (2020) *Science*, 368 (6489), pp. 409-412.
COI: 1:CAS:528:DC%2BB3cXnsIKrtL8%3D
- Shalayel, M.H., Al-Mazaidh, G.M., Aladaileh, S.H., Al-Swailmi, F.K., Al-Thiabat, M.G.
Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15
(2020) *Pakistan Journal of Pharmaceutical Sciences*, 33 (5), pp. 2179-2186.
COI: 1:CAS:528:DC%2BB3cXit1ensL%2FM
 - Kim, Y., Jedrzejczak, R., Maltseva, N.I., Wilamowski, M., Endres, M., Godzik, A., Joachimiak, A.
Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2
(2020) *Protein Science*, 29 (7), pp. 1596-1605.
COI: 1:CAS:528:DC%2BB3cXosVWrsbo%3D
 - Yadav, R., Chaudhary, J.K., Jain, N., Chaudhary, P.K., Khanra, S., Dhamija, P., Handu, S.
Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19
(2021) *Cells*, 10 (4), p. 821.
COI: 1:CAS:528:DC%2BB3MXhvf2iu7bN
 - Liu, C., Zhou, Q., Li, Y., Garner, L.V., Watkins, S.P., Carter, L.J., Albaiu, D.
Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases
(2020) *ACS Central Science*, 6, pp. 315-331.
COI: 1:CAS:528:DC%2BB3cXkslWrsbo%3D
 - Joshi, T., Joshi, T., Sharma, P., Mathpal, S., Pundir, H., Bhatt, V., Chandra, S.
In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
(2020) *European Review of Medical Pharmacological Science*, 24 (8), pp. 4529-4536.
COI: 1:STN:280:DC%2BB38vjsFCnsg%3D%3D
 - *Naming the Coronavirus Disease (COVID-19) and the Virus that Causes It*,
Accessed on Aug 25, 2022
 - Majumder, R., Mandal, M.
Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: An in silico docking and molecular dynamics simulation approach
(2022) *Journal of Biomolecular Structure and Dynamics*, 40 (2), pp. 696-711.
COI: 1:CAS:528:DC%2BB3cXhvVWhu7bP
 -
 - Burki, T.K.
The role of antiviral treatment in the COVID-19 pandemic
(2022) *The Lancet Respiratory Medicine*, 10 (2).
COI: 1:CAS:528:DC%2BB38XhsVWmu74%3D
 - Vardhan, S., Sahoo, S.K.
In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19
(2020) *Computers in Biology and Medicine*, 124, p. 103936.
COI: 1:CAS:528:DC%2BB3cXhsFShsLbN
 - Ali, A., Sepay, N., Afzal, M., Sepay, N., Alarifi, A., Shahid, M., Ahmad, M.
Molecular designing, crystal structure determination and in silico screening of copper (II) complexes bearing 8-hydroxyquinoline derivatives as anti-COVID-19
(2021) *Bioorganic Chemistry*, 110, p. 104772.
COI: 1:CAS:528:DC%2BB3MXlvF2ms7g%3D

- Antonio, A.S., Wiedemann, L.S.M., Galante, E.B.F., Guimarães, A.C., Matharu, A.S., Veiga-Junior, V.F.
Efficacy and sustainability of natural products in COVID-19 treatment development: Opportunities and challenges in using agro-industrial waste from Citrus and apple (2021) *Heliyon*, 7 (8).
COI: 1:CAS:528:DC%2BB38XhsVOru7nl
- Gyselinck, I., Janssens, W., Verhamme, P., Vos, R.
Rationale for azithromycin in COVID-19: An overview of existing evidence (2021) *BMJ Open Respiratory Research*, 8 (1).
- Cragg, G.M., Newman, D.J.
Natural product drug discovery in the next millennium (2001) *Pharmaceutical Biology*, 39 (sup1), pp. 8-17.
COI: 1:CAS:528:DC%2BD38XltVSmuro%3D
- Basnet, B.B., Liu, H., Liu, L., Suleimen, Y.M.
Diversity of anticancer and antimicrobial compounds from lichens and lichen-derived fungi: A systematic review (1985–2017) (2018) *Current Organic Chemistry*, 22 (25), pp. 2487-2500.
COI: 1:CAS:528:DC%2BC1MXhvVWjt7c%3D
- Bhattacharyya, S., Deep, P.R., Singh, S., Nayak, B.
Lichen secondary metabolites and its biological activity (2016) *American Journal of PharmTech Research*, 6 (6), pp. 1-7.
- Fernández-Moriano, C., Gómez-Serranillos, M.P., Crespo, A.
Antioxidant potential of lichen species and their secondary metabolites: A systematic review (2016) *Pharmaceutical Biology*, 54 (1), pp. 1-17.
- Joshi, T., Sharma, P., Joshi, T., Chandra, S.
In silico screening of anti-inflammatory compounds from Lichen by targeting cyclooxygenase-2 (2020) *Journal of Biomolecular Structure and Dynamics*, 38 (12), pp. 3544-3562.
COI: 1:CAS:528:DC%2BC1MXhslOKsLrP
- Sahoo, B., Dash, S., Parida, S., Sahu, J.K., Rath, B.
Antimicrobial activity of the lichens Parmotrema andium and Dirinaria applanata (2021) *Journal of Applied Biology and Biotechnology*, 9 (4), p. 97.
- Van Cuong, T., Thoa, N.T.
Bioactive compounds from lichens as promising biomaterial for the treatment of influenza virus: A (2018) *Journal of Scientific Research & Reports*, 18 (4), pp. 1-15.
- Sokolov, D.N., Zarubaev, V.V., Shtro, A.A., Polovinka, M.P., Luzina, O.A., Komarova, N.I., Kiselev, O.I.
Antiviral activity of (-)-and (+)-usnic acids and their derivatives against influenza virus A (H1N1) 2009 (2012) *Bioorganic & Medicinal Chemistry Letters*, 22 (23), pp. 7060-7064.
COI: 1:CAS:528:DC%2BC38XhsFOmtL%2FE
- Luzina, O.A., Salakhutdinov, N.F.
Usnic acid and its derivatives for pharmaceutical use: A patent review (2000–2017) (2018) *Expert Opinion on Therapeutic Patents*, 28 (6), pp. 477-491.
COI: 1:CAS:528:DC%2BC1cXptFSktLs%3D
- Shtro, A.A., Zarubaev, V.V., Luzina, O.A., Sokolov, D.N., Kiselev, O.I., Salakhutdinov, N.F.
Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A

virus

(2014) *Bioorganic & Medicinal Chemistry*, 22 (24), pp. 6826-6836.

COI: 1:CAS:528:DC%2BC2cXhvVOntLnN

- Barrera Tomas, M., Tomas Chota, G.E., Sheen Cortavarría, P., Fuentes Bonilla, P., Inocente Camones, M.A., Contreras, J.S.
Synthesis of acyl-hydrazone from usnic acid and isoniazid and its anti-Myco bacterium tuberculosis activity
(2017) *Revista Colombiana de Química*, 46 (3), pp. 17-21.
- Araújo, A.A.S., De Melo, M.G.D., Rabelo, T.K., Nunes, P.S., Santos, S.L., Serafini, M.R., Gelain, D.P.
Review of the biological properties and toxicity of usnic acid
(2015) *Natural Product Research*, 29 (23), pp. 2167-2180.
- Shtro, A.A., Zarubaev, V.V., Luzina, O.A., Sokolov, D.N., Salakhutdinov, N.F.
Derivatives of usnic acid inhibit broad range of influenza viruses and protect mice from lethal influenza infection
(2015) *Antiviral Chemistry and Chemotherapy*, 24 (3-4), pp. 92-98.
COI: 1:STN:280:DC%2BC28fksFWmug%3D%3D
- Snetkov, P., Morozkina, S., Olekhovich, R., Vu, T.H.N., Tyanutova, M., Uspenskaya, M.
Curcumin/usnic acid-loaded electrospun nanofibers based on hyaluronic acid
(2020) *Materials*, 13 (16), p. 3476.
COI: 1:CAS:528:DC%2BB3cXhsl2gsbrP
- Takai, M., Uehara, Y., Beisler, J.A.
Usnic acid derivatives as potential antineoplastic agents
(1979) *Journal of Medicinal Chemistry*, 22 (11), pp. 1380-1384.
COI: 1:CAS:528:DyaE1MXIs1yhs7Y%3D
- Prateeksha, G., Rana, T.S., Asthana, A.K., Singh, B.N., Barik, S.K.
Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches
(2021) *Journal of Molecular Structure*, 1240, p. 130506.
COI: 1:CAS:528:DC%2BB3MXhtVKmu7bL
- Pires, D.E., Blundell, T.L., Ascher, D.B.
pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures
(2015) *Journal of Medicinal Chemistry*, 58 (9), pp. 4066-4072.
COI: 1:CAS:528:DC%2BC2MXmtlams7w%3D
- Dai, W., Zhang, B., Jiang, X.M., Su, H., Li, J., Zhao, Y., Liu, H.
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
(2020) *Science*, 368 (6497), pp. 1331-1335.
COI: 1:CAS:528:DC%2BB3cXht1alsrzL
- Amin, S., Banerjee, S., Singh, S., Qureshi, I.A., Gayen, S., Jha, T.
First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: An endeavor on COVID-19 drug discovery
(2021) *Molecular Diversity*, 25 (3), pp. 1827-1838.
COI: 1:CAS:528:DC%2BB3MXmtVOhsA%3D%3D
- Mishra, P.M., Nandi, C.K.
Structural Decoding of a Small Molecular Inhibitor on the Binding of SARS-CoV-2 to the ACE 2 Receptor
(2021) *The Journal of Physical Chemistry B*, 125 (30), pp. 8395-8405.
COI: 1:CAS:528:DC%2BB3MXhs1Smtb7M

- Padhi, A.K., Seal, A., Khan, J.M., Ahamed, M., Tripathi, T.
Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations
(2021) *European Journal of Pharmacology*, 894, p. 173836.
COI: 1:CAS:528:DC%2BB3MXosFSgsQ%3D%3D
- Liu, Y., Grimm, M., Dai, W.T., Hou, M.C., Xiao, Z.X., Cao, Y.
CB-Dock: A web server for cavity detection-guided protein–ligand blind docking
(2020) *Acta Pharmacologica Sinica*, 41 (1), pp. 138-144.
- Huggins, D.J.
Comparing the performance of different AMBER protein forcefields, partial charge assignments, and water models for absolute binding free energy calculations
(2022) *Journal of Chemical Theory and Computation*, 18 (4), pp. 2616-2630.
COI: 1:CAS:528:DC%2BB38XmsFeitLo%3D
- Bhardwaj, V., Singh, R., Singh, P., Purohit, R., Kumar, S.
Elimination of bitter-off taste of stevioside through structure modification and computational interventions
(2020) *Journal of Theoretical Biology*, 486, p. 110094.
COI: 1:CAS:528:DC%2BC1MXitlehu7bP
- Kagami, L.P., das Neves, G.M., Timmers, L.F.S.M., Caceres, R.A., Eifler-Lima, V.L.
Geo-Measures: A PyMOL plugin for protein structure ensembles analysis
(2020) *Computational Biology and Chemistry*, 87, p. 107322.
COI: 1:CAS:528:DC%2BB3cXhtlSitb3E
- Bhupinder Singh, K.
Practitioners section-Cytochrome P450 enzyme isoforms and their therapeutic implications: An update
(2007) *Indian Journal of Medical Sciences*, 61 (2), pp. 102-116.
- Gianulis, E.C., Trudeau, M.C.
Rescue of aberrant gating by a genetically encoded PAS (Per-Arnt-Sim) domain in several long QT syndrome mutant human ether-a-go-go-related gene potassium channels
(2011) *Journal of Biological Chemistry*, 286 (25), pp. 22160-22169.
COI: 1:CAS:528:DC%2BC3MXns1Kks7w%3D
- Aromolaran, A.S., Srivastava, U., Alí, A., Chahine, M., Lazaro, D., El-Sherif, N., Boutjdir, M.
Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation
(2018) *PLoS ONE*, 13 (12).
- Nattel, S., Carlsson, L.
Innovative approaches to anti-arrhythmic drug therapy
(2006) *Nature Reviews Drug Discovery*, 5 (12), pp. 1034-1049.
COI: 1:CAS:528:DC%2BD28Xht1Kju7vJ
- Bhardwaj, V.K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., Kumar, S.
Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors
(2020) *Journal of Biomolecular Structure and Dynamics*, 39 (10), pp. 3449-3458.
- Al Adem, K., Ferreira, J.C., Fadl, S., Rabeh, W.M.
pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity
(2022) *Journal of Biological Chemistry*, 299, p. 102790.

- Weng, Y.L., Naik, S.R., Dingelstad, N., Lugo, M.R., Kalyanamoorthy, S., Ganesan, A.
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
(2021) *Scientific Reports*, 11 (1), pp. 1-22.

Correspondence Address

Aluwi M.F.F.M.; Faculty of Industrial Sciences and Technology, Pahang Darul Makmur, Malaysia; email: fasihi@ump.edu.my
Huq A.K.M.M.; Bio Aromatic Research Centre, Pahang Darul Makmur, Malaysia; email: moyeenul@ump.edu.my

Publisher: Springer

ISSN: 10736085

PubMed ID: 36752937

Language of Original Document: English

Abbreviated Source Title: Mol. Biotechnol.

2-s2.0-85147679713

Document Type: Article

Publication Stage: Article in Press

Source: Scopus

ELSEVIER

Copyright © 2023 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

 RELX Group™